Bemfivastatin hemicalcium - CAS 805241-64-9

Bemfivastatin hemicalcium (PPD 10558), an orally active HMG-CoA reductase inhibitor, serves as a lipid-lowering agent. It amplifies liver extract activity and exhibits no-observed adverse effect levels (NOAEL) at dosages of ≥320 mg/kg/d for rat developmental toxicity, ≥12.5 mg/kg/d for rabbit maternal toxicity, and ≥25 mg/kg/d for rabbit developmental toxicity. This compound is utilized in research concerning hypercholesterolemic myalgia in patients intolerant to statins.

Others, HMG-CoA Reductase

Metabolism, Others

805241-64-9

C34H36FN2O6.1/2Ca

607.67

[O-]C(C[C@H](O)C[C@H](O)CCN1C(C2=CC=C(C=C2)F)=C(C3=CC=CC=C3)C(C(NC4=CC=C(C=C4)CO)=O)=C1C(C)C)=O.[Ca+2]

-20°C

Ice Packs

Small Compound